Abstract
Rituximab is an effective and welltolerated new treatment option for patients with B-cell malignancies that are positive for the surface antigen CD20. Among its attributes are: minimal myelosuppression1; minimal other toxicities that are nonoverlapping with those of standard chemotherapy1; a different mechanism of action than chemotherapy2; and possible sensitization of lymphoma cells to the cytotoxic effects of chemotherapy.3 Based on these observations, rituximab seems ideally suited for use in conjunction with chemotherapy. In the current issue of Clinical Lymphoma, Emmanouilides et al report on an encouraging pilot trial utilizing rituximab following a mild chemotherapy program of mitoxantrone and cyclophosphamide for the treatment of patients with indolent lym
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
